2. Search Result
Search Result
Results for "

CDK

" in MedChemExpress (MCE) Product Catalog:

701

Inhibitors & Agonists

4

Screening Libraries

1

Fluorescent Dye

12

Peptides

29

Natural
Products

92

Recombinant Proteins

12

Isotope-Labeled Compounds

21

Antibodies

6

Click Chemistry

57

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W478102
    CDK2-IN-13

    		CDK Cancer
    CDK2-IN-13 (Compound 15) is a CDK2 inhibitor with an IC50 of 12 µM. CDK2-IN-13 can be used in research of cancer .
    CDK2-IN-13
  • HY-147386
    CDK-IN-10

    		CDK Cancer
    CDK-IN-10 (example 54) is a cyclin dependent kinase (CDK) inhibitor that can be used in cancer research .
    CDK-IN-10
  • HY-164664
    CDK2-IN-30

    		CDK Cancer
    CDK2-IN-30 (Formula (I)) is a CDK2 inhibitor with an IC50 value ≤20 nM. CDK2-IN-30 can be used in tumor research .
    CDK2-IN-30
  • HY-164376
    CDK4/6-IN-21

    		CDK Cancer
    CDK4/6-IN-21 (compound I-52) is a CDK4/6 inhibitor with IC50 values of 3.88 and 3.31 nM for CDK4 and CDK6, respectively. CDK4/6-IN-21 has antitumor activity .
    CDK4/6-IN-21
  • HY-164376A
    CDK4/6-IN-21 maleate

    		CDK Cancer
    CDK4/6-IN-21 maleate (compound I-52) is a CDK4/6 inhibitor with IC50 values of 3.88 and 3.31 nM for CDK4 and CDK6, respectively. CDK4/6-IN-21 maleate has antitumor activity .
    CDK4/6-IN-21 maleate
  • HY-153336
    CDK-IN-12

    		CDK Cancer
    CDK-IN-12 (Example 20) is a CDK Inhibitor. CDK-IN-12 Inhibits CDK4/6 with IC50 values less than 20 nM .
    CDK-IN-12
  • HY-169048
    CDK2/4-IN-2

    		CDK Cancer
    CDK2/4-IN-2 (compound 56) is a CDK2 and CDK4 dual inhibitor with IC50s less than 100 nM. CDK2/4-IN-2 can be used in the study of cancer .
    CDK2/4-IN-2
  • HY-158170
    CDK7-IN-28

    		CDK Cancer
    CDK7-IN-28 (CDK7-1276) is a potent CDK7 inhibitor(IC50＜5 nM). CDK7-IN-28 can inhibit proliferation of MDA-MB-468 cell line by blocking cell cycle and inhibiting DNA replication .
    CDK7-IN-28
  • HY-169246
    CDK2-IN-32

    		CDK Apoptosis Cancer
    CDK2-IN-32 (Compound 5g) is a selective CDK2 inhibitor with an IC50 of 0.21 μM. CDK2-IN-32 shows cytotoxicity against Vero cells with an IC50 of 28.52 μM .
    CDK2-IN-32
  • HY-161978
    CDK4/6-IN-22

    		CDK Cancer
    CDK4/6-IN-22 (Compound 1-A) is a CDK4 and CDK6 dual inhibitor .
    CDK4/6-IN-22
  • HY-146253
    CDK1/2/4-IN-1

    		CDK Apoptosis Bcl-2 Family Caspase Cancer
    CDK1/2/4-IN-1 (compound 3a) is a potent CDK inhibitor with IC50 values of 1.47, 0.78 and 0.87 μM for CDK1, CDK2 and CDK4, respectively. CDK1/2/4-IN-1 arrests cell cycle at G2/M phase and induces apoptosis. CDK1/2/4-IN-1 elevates Bax, caspase-3, P53 levels and decreases Bcl-2 level. CDK1/2/4-IN-1 can be used for cancer research .
    CDK1/2/4-IN-1
  • HY-157297
    CDK-IN-13

    		CDK Cancer
    CDK-IN-13 (compound 32E) is a potent and selective inhibitor of CDK12/cyclinK with an IC50 of 3 nM. CDK-IN-13 inhibits the growth of the HER2-positive breast cancer cell lines .
    CDK-IN-13
  • HY-149819
    CDK/HDAC-IN-3

    		HDAC CDK Cancer
    CDK/HDAC-IN-3 is an orally active HDACs/CDKs dual inhibitor. CDK/HDAC-IN-3 has potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2 and HDAC3 with IC50 values of 98.32 nM, 98.85 nM, 100 nM, 62.12 nM, 93.28nM and 82.87 nM. CDK/HDAC-IN-3 can be used for the acute myeloid leukemia (AML) .
    CDK/HDAC-IN-3
  • HY-169075
    CDK/HDAC-IN-4

    		HDAC CDK Apoptosis Cancer
    CDK/HDAC-IN-4 is a high selective dual cyclin-dependent kinase (CDK)/histone deacetylase (HDAC) inhibitor with IC50 values of 88.4 and 168.9 nM, respectively. CDK/HDAC-IN-4 exhibits antiproliferative capacities against hematological and solid tumor cells. CDK/HDAC-IN-4 also induces MV-4-11 cell Apoptosis and S cell cycle arrests. CDK/HDAC-IN-4 possesses a significant antitumor potency in the MV-4-11 xenograft model .
    CDK/HDAC-IN-4
  • HY-151878
    CDK7-IN-20

    		CDK GSK-3 Metabolic Disease
    CDK7-IN-20 is a potent, selective and irreversible CDK7 (CDK) inhibitor with an IC50 value of 4 nM. CDK7-IN-20 displays >206-fold selectivity for CDK7 over CDK1, CDK2, CDK3, CDK5, CDK6, CDK9 and CDK12 . CDK7-IN-20 has the potential for autosomal dominant polycystic kidney disease (ADPKD) research .
    CDK7-IN-20
  • HY-147905
    CDK9-IN-18

    		CDK Apoptosis Cancer
    CDK9-IN-18 is a potent CDK9 inhibitor. CDK9-IN-18 blocks the phosphorylation function of kinase CDK9. CDK9-IN-18 exhibits both good anticancer activity and low cellular activity. CDK9-IN-18 induces apoptosis.
    CDK9-IN-18
  • HY-112626
    CDK12-IN-2

    		CDK Cancer
    CDK12-IN-2 is a potent, selective and nanomolar CDK12 inhibitor (IC50=52 nM) with good physicochemical properties. CDK12-IN-2 is also a strong CDK13 inhibitor due to CDK13 is the closest homologue of CDK12. CDK12-IN-2 shows excellent kinase selectivity for CDK12 over CDK2, 9, 8, and 7. CDK12-IN-2 inhibits the phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II. CDK12-IN-2 can be used an excellent chemical probe for functional studies of CDK12 .
    CDK12-IN-2
  • HY-162619
    CDK9-IN-33

    		Apoptosis CDK Cancer
    CDK9-IN-33 (compound C35) is a potent, selective and orally active CDK9 inhibitor with IC50 values of 17.44, 160, 316.30, 1771.00, >10000 nM for CDK9, CDK7, CDK2, CDK4, CDK6 respectively. CDK9-IN-33 induces apoptosis. CDK9-IN-33 decreases the protein expression of RPB1 CTD Ser2, RPB1, MCL1. CDK9-IN-33 shows anti-tumor activity .
    CDK9-IN-33
  • HY-145655
    CDK7-IN-11

    		CDK Cancer
    CDK7-IN-11 is an orally active CDK7 inhibitor. CDK7-IN-11 exhibits high CDK7 inhibitory activity with IC50 value of 4.2 nM. CDK7-IN-11 can be effectively used for the research of diseases associated with CDK7 .
    CDK7-IN-11
  • HY-153950
    CDK7-IN-22

    		CDK Cancer
    CDK7-IN-22 (compound 101) is an CDK7 inhibitor with antitumor activity. CDK7-IN-22 shows selectivity on CDK7 .
    CDK7-IN-22
  • HY-130001
    CDK9-IN-9

    		CDK Cancer
    CDK9-IN-9 (example 2) is a potent and selective CDK9 inhibitor with an IC50 of 1.8 nM. CDK9-IN-9 inhibits CDK2 with an IC50 of 155 nM. CDK9-IN-9 has anti-cancer activity .
    CDK9-IN-9
  • HY-151984
    CDK9-IN-22

    		CDK Cancer
    CDK9-IN-22 is a potent CDK9 inhibitor with IC50s of 10.4, 876.2 nM for CDK9, CDK, respectively. CDK9-IN-22 induces apoptosis and cell cycle arrests at G2/M phase. CDK9-IN-22 decreases the expression of p-RNAPII (S2) and CDK9 protein. CDK9-IN-22 shows antiproliferative and aiti-tumor activity .
    CDK9-IN-22
  • HY-145394
    CDK7-IN-6

    		CDK Cancer
    CDK7-IN-6 is a potent and selective cyclin-dependent kinase (CDK7) inhibitor (IC50≤100 nM), extracted from patent WO2019197549 A1, compound 210. CDK7-IN-6 is > 200-fold selective for CDK7 over CDK1, CDK2, and CDK5. CDK7-IN-6 can be used for the research of cancer .
    CDK7-IN-6
  • HY-151409
    CDK1-IN-5

    		CDK Cancer
    CDK1-IN-5 (10h) is a selective CDK1 inhibitor with IC50s of 42.19, 188.71 and 354.15 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-5 inhibits growth of cancer cells by affecting cell cycle. CDK1-IN-5 can be used for the research of cancer .
    CDK1-IN-5
  • HY-151407
    CDK1-IN-3

    		CDK Cancer
    CDK1-IN-3 (8g) is a selective CDK1 inhibitor with IC50s of 36.8, 305.17 and 369.37 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-3 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-3 can be used for the research of cancer .
    CDK1-IN-3
  • HY-P2559
    CDK7/9 tide

    		CDK Cancer
    CDK7/9 tide is peptide substrate for CDK7 or CDK9 .
    CDK7/9 tide
  • HY-144810
    CDK2-IN-8

    		CDK Cancer
    CDK2-IN-8 is a potent CDK2 inhibitor with an IC50 of 1.74 µM. CDK2-IN-8 shows antiproliferative activity. CDK2-IN-8 has the potential for the research of melanoma .
    CDK2-IN-8
  • HY-151408
    CDK1-IN-4

    		CDK Cancer
    CDK1-IN-4 (10d) is a selective CDK1 inhibitor with IC50s of 44.52, 624.93 and 135.22 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN4 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-4 can be used for the research of cancer .
    CDK1-IN-4
  • HY-130852
    CDK9-IN-11

    		CDK Ligands for Target Protein for PROTAC Cancer
    CDK9-IN-11 is a potent CDK9 inhibitor. CDK9-IN-11 is the ligand for the PROTAC CDK9 Degrader-1 (HY-103628) .
    CDK9-IN-11
  • HY-130850
    CDK9-IN-10

    		CDK Ligands for Target Protein for PROTAC Cancer
    CDK9-IN-10 is a potent CDK9 inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811) .
    CDK9-IN-10
  • HY-155602
    CDK2-IN-18

    		CDK Cancer
    CDK2-IN-18 (compound 8q) is a potent inhibitor of CDK2/E and CDK4/D1, with IC50s of 8 nM and 46 nM, respectively. CDK2-IN-18 inhibits the proliferation of tumor cells .
    CDK2-IN-18
  • HY-145693
    CDK5-IN-2

    		CDK Others
    CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor with IC50s of 0.2 and 23 for CDK5/p25 and CDK2/CycA, respectively .
    CDK5-IN-2
  • HY-160643
    CDK2-IN-27

    		CDK Cancer
    CDK2-IN-27 (compound 1) is a potent CDK2 inhibitor with IC50 values of <10, >10-20 nM for CDK2/cyclin E1, CDK2/cyclin B1, respectively .
    CDK2-IN-27
  • HY-150641
    CDK-IN-9

    		CDK Apoptosis DNA/RNA Synthesis Cancer
    CDK-IN-9 (compound 24) is a potent CDK inhibitor, also as a molecular glue inducing an interaction between CDK12 and DDB1, with an IC50 values of 4 nM for CDK2/E. CDK-IN-9 leads to polyubiquitination of cyclin K and its subsequent degradation. CDK-IN-9 induce apoptosis through dephosphorylation of retinoblastoma protein and RNA polymerase II .
    CDK-IN-9
  • HY-139725
    CDK5-IN-1

    		CDK Metabolic Disease
    CDK5-IN-1, a potent CDK5 inhibitor, is against CDK5 activity less than 10 nM. CDK5-IN-1 is used for kidney diseases research .
    CDK5-IN-1
  • HY-145694
    CDK5-IN-3

    		CDK Metabolic Disease
    CDK5-IN-3 (compound 11) is a potent and selective CDK5 inhibitor, with IC50s of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA, respectively. CDK5-IN-3 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD) .
    CDK5-IN-3
  • HY-13033
    CDK-IN-2
    1 Publications Verification

    CDK inhibitor II

    		 CDK Cancer
    CDK-IN-2 is a potent and specific CDK9 inhibitor with IC50 of <8 nM, extracted from reference 1, example 4.
    CDK-IN-2
  • HY-144811
    CDK2-IN-9

    		CDK Apoptosis Cancer
    CDK2-IN-9 is a potent CDK2 inhibitor with an IC50 of 0.63 µM. CDK2-IN-9 shows antiproliferative activity. CDK2-IN-9 induces apoptosis and cell cycle arrest at S and G2/M phase. CDK2-IN-9 has the potential for the research of melanoma .
    CDK2-IN-9
  • HY-126251
    CDK9-IN-7

    		CDK Apoptosis Cancer
    CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC .
    CDK9-IN-7
  • HY-151463
    CDK8-IN-11

    		CDK β-catenin Cancer
    CDK8-IN-11 is a potent and selective CDK8 inhibitor with an IC50 value of 46 nM. CDK8-IN-11 inhibits WNT/β-catenin signaling pathway. CDK8-IN-11 can be used in the research of colon cancer .
    CDK8-IN-11
  • HY-151463A
    CDK8-IN-11 hydrochloride

    		CDK β-catenin Cancer
    CDK8-IN-11 hydrochloride is a potent and selective CDK8 inhibitor with an IC50 value of 46 nM. CDK8-IN-11 hydrochloride inhibits WNT/β-catenin signaling pathway. CDK8-IN-11 hydrochloride can be used in the research of colon cancer .
    CDK8-IN-11 hydrochloride
  • HY-126244
    CDK4/6-IN-3

    		CDK Cancer
    CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor with Kis of <0.3 nM and 2.2 nM, respectively. CDK4/6-IN-3 inhibits CDK1 with a Ki of 110 nM. CDK4/6-IN-3 can be used for the treatment of glioblastoma .
    CDK4/6-IN-3
  • HY-115924
    CDK1-IN-1

    		CDK Cancer
    CDK1-IN-1 is a potent CDK1 inhibitor (CDK1/CycB IC50=161.2 nM) with potential antiproliferative activity and selectivity for cancer tissues. CDK1-IN-1 induces apoptosis in p53 dependent manner through the intrinsic apoptotic pathway. CDK1-IN-1 is a potential targeted antitumor agent .
    CDK1-IN-1
  • HY-149974
    CDK8-IN-13

    		Apoptosis CDK Cancer
    CDK8-IN-13 is a potent, selective and orally active CDK8 inhibitor with an IC50 value of 51.9 nM. CDK8-IN-13 induces Apoptosis. CDK8-IN-13 decreases the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 shows antitumor activity .
    CDK8-IN-13
  • HY-160941
    CDK2-IN-29

    		CDK Cancer
    CDK2-IN-29 (Compound 13q) is an inhibitor for cyclin-dependent kinase (CDK), with IC50 of 96 nM and 360 nM, for CDK 2 and CDK 4, respectively .
    CDK2-IN-29
  • HY-162255
    CDK2-IN-23

    		CDK Cancer
    CDK2-IN-23 (Compound 17) is a kinase selective and highly potent CDK2 inhibitor (IC50 = 0.29 nM). CDK2-IN-23 shows the pharmacodynamic inhibition of CDK2 in CCNE1-amplified mouse models. CDK2-IN-23 can be used for the research of cancer .
    CDK2-IN-23
  • HY-163856
    CDK7-IN-30

    		Apoptosis CDK Cancer
    CDK7-IN-30 (Compound 22) is a CDK7 inhibitor (IC50 = 7.21 nM) that effectively inhibits the phosphorylation of RNA Polymerase II and CDK2. CDK7-IN-30 CDK7-IN-30 can induce cell apoptosis and has anti-cancer activity and can be used in cancer research .
    CDK7-IN-30
  • HY-139328
    CDK12-IN-5

    		CDK Cancer
    CDK12-IN-5, a pyrazolotriazine, is a potent CDK12 inhibitor with an IC50 of 23.9 nM at high ATP (2 mM). CDK12-IN-5 has no effect on CDK2/Cyclin E (IC50=173 μM) and CDK9/Cyclin T1 (IC50=127 μM) at high ATP (2 mM) (WO2021116178A1) .
    CDK12-IN-5
  • HY-144175
    CDK7-IN-12

    		CDK Cancer
    CDK7-IN-12 is a potent inhibitor of CDK7. CDK7-IN-12 plays a key role in transcriptional regulation and cell cycle regulation. CDK7-IN-12 effectively inhibit malignant tumor proliferation in vitro and in vivo. CDK7-IN-12 has the potential for the research of cancer disease (extracted from patent WO2021249417A1, compound 43) .
    CDK7-IN-12
  • HY-151580
    CDK2-IN-14

    		CDK Cancer
    CDK2-IN-14 (compound 4f) is a highly selective CDK2 inhibitor. CDK2-IN-14 can be used in research of cancer .
    CDK2-IN-14

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: